Preclinical studies have supported the potential use of PARPi as an immunostimulatory agent in combination with ICIs through the activation of cGAS‐STING signaling [11, 12] and the increase of tumor mutational burden in TNBC with either gBRCAm or gBRCAwt [12]. The gene discussed is STING1; the disease is neoplasm.